Cross-Class Synthesis — Clinical Decision-Making in ADHD Pharmacotherapy & Breastfeeding
IThe Evidence Hierarchy
Across five chapters and five drug classes, a clear evidence hierarchy has emerged for breastfeeding — and it differs meaningfully from the pregnancy hierarchy. In pregnancy, the evidence tiers are defined by teratogenicity and obstetric outcomes. In breastfeeding, the tiers are defined by three variables: (1) measured relative infant dose (RID), (2) published infant outcome data, and (3) FDA label posture.
Methylphenidate & Atomoxetine
Amphetamines & Viloxazine
Clonidine & Guanfacine
The Overarching Guidance Principle
ACOG Clinical Practice Guideline No. 5 (2023) states: "individuals with mental health conditions should not be discouraged from breastfeeding if that is their desired form of infant feeding" and explicitly recommends against withholding or discontinuing mental-health medications due to pregnancy or lactation status alone.13
AAFP 2022 (Spencer et al.) emphasizes: "effectively treating the mother is the highest priority because this allows for the most effective parenting and bonding."14
AAP 2022 Technical Report (Meek & Noble): "most maternal medications... are compatible with breastfeeding," and directs clinicians to LactMed for individual medication safety data.15
IIMaster Comparison Table
| Feature | Methylphenidate | Atomoxetine | Viloxazine | Amphetamines | Clonidine | Guanfacine |
|---|---|---|---|---|---|---|
| Evidence tier | Tier 1 | Tier 1 | Tier 2 | Tier 2 | Tier 3 | Tier 3 |
| RID | 0.16–0.7% | 0.19% | ~1% | 2–13.8% | 4.1–8.4% | Unknown |
| Infant serum | Undetectable | Not measured | Not measured | 5–15% maternal | ~50% maternal | Unknown |
| Infant outcome data | n=9–12 (no AEs) | n=10 (no AEs) | None (PK-only) | n=13–36 (mild AEs ~38%) | 1 combined-exposure case | None |
| FDA label | Supports shared DM | Supports shared DM (label not yet updated) | Supports shared DM (Jan 2025 update) | "Not recommended" | "Exercise caution" | No human data; supports BF |
| Milk supply concern | Theoretical only | None | Unknown | FDA warns (prolactin suppression) | Complex, bidirectional | Unknown |
| Abuse potential | Schedule II | None | None | Schedule II | Minimal | Minimal |
| Key interaction | Halogenated anesthetics | CYP2D6 inhibitors (10-fold) | Strong CYP1A2 (caffeine) | Antacids/PPIs | Beta-blockers (rebound) | CYP3A4 |
| Onset of action | Hours | 4–6 weeks | Steady state 2 days | Hours | 1–2 weeks | 1–2 weeks |
| Boxed warning | None | Suicidality | Suicidality | Abuse/dependence | None | None |
| Protein binding | ~15% | 98% | 76–82% | ~20% | 20–40% | ~70% |
| Half-life | 2–3 h | 5 h (EM); 22 h (PM) | ~7 h | 10–13 h | 12–16 h | ~17 h |
| Metabolism | CES1 (hepatic) | CYP2D6 (hepatic) | CYP2D6 + UGT | CYP2D6 + renal (pH-dependent) | Hepatic (CYP2D6 + CYP1A2/3A4) + renal (~40–60% unchanged) | CYP3A4 |
| Expert consensus | Preferred stimulant | Preferred non-stimulant | Acceptable if others failed | Caution · monitor | Caution · LactMed prefers alternatives | Insufficient data |
| Best BF use case | Default stimulant | SUD history; non-stimulant need | Failed all others; fast non-stimulant onset | Stable on amph; MPH not tolerated | Dual indication (HTN, tics) | Dual indication; no human BF data |
IIIDecision Framework: Which Drug for Which Patient?
Does the patient plan to breastfeed?
Is the patient currently on an ADHD medication?
What is the current medication?
Are there specific risk factors that favor a switch?
Selecting a new agent for breastfeeding
Apply the scenario table below. Match the clinical picture to the preferred agent based on Tier 1 hierarchy and patient-specific factors.
The Scenario Table
| Clinical Scenario | Preferred Agent & Rationale |
|---|---|
| Moderate-severe ADHD, no specific contraindications, breastfeeding priority | Methylphenidate — Tier 1; lowest RID among stimulants; undetectable in infant serum; FDA label supports BF; fastest onset (hours). LactMed: "If methylphenidate is required by the mother, it is not a reason to discontinue breastfeeding."1,2,16 |
| ADHD with SUD history or stimulant contraindication | Atomoxetine — Tier 1; lowest measured RID of any ADHD medication (0.19%); no abuse potential; not scheduled. Allow 4–6 weeks for full effect; bridge with low-dose MPH if functional impairment severe during transition.3 |
| ADHD with comorbid chronic hypertension or tic disorder | Clonidine or guanfacine (dual benefit). Clonidine has human BF data (RID 4.1–8.4%) but one combined-exposure adverse event case; guanfacine has no human data. Monitor infant for sedation, hypotonia, poor feeding. If HTN is the dual indication, consider whether labetalol or nifedipine + methylphenidate would be a cleaner combination.9,10,12 |
| ADHD stable on amphetamine; MPH not tolerated or previously failed | Continue amphetamine — Tier 2; RID 2–13.8% but no serious AEs reported; LactMed supports use with monitoring. Document FDA label override and clinical rationale.5,6,11 |
| Failed all other agents; needs fast non-stimulant onset | Viloxazine — Tier 2; RID ~1%; steady state in 2 days (vs. atomoxetine 4–6 weeks). Counsel strict caffeine limitation (CYP1A2 trap). No infant outcome data — disclose this gap.7 |
| Mild ADHD; patient prefers non-pharmacologic management during BF | CBT, coaching, environmental modifications — no medication exposure risk. Resume pharmacotherapy when breastfeeding concludes or if functional impairment worsens. |
IVThe Pregnancy-to-Postpartum Transition
The transition from pregnancy to breastfeeding is the most common clinical decision point in this course. The pregnancy and breastfeeding evidence hierarchies differ, creating opportunities for optimization.
Pregnancy → Breastfeeding Transition Map
| Pregnancy Medication | Breastfeeding Action |
|---|---|
| Amphetamine (continued through pregnancy) | Offer switch to MPH for breastfeeding (Tier 1 vs. Tier 2). If patient declines, continue with monitoring. MPH onset is within hours — can switch immediately postpartum without functional gap. |
| Methylphenidate (continued through pregnancy) | Continue. Already the preferred BF stimulant. No change needed. |
| Atomoxetine (continued through pregnancy) | Continue. Tier 1 for BF. Check CYP2D6 status; review for new postpartum CYP2D6 inhibitors (especially SSRI switches for PPD). |
| Guanfacine or clonidine (continued through pregnancy) | If for ADHD only, consider switch to atomoxetine or MPH (lower RIDs, more infant data). If dual indication, continue with monitoring. Never stop alpha-2 agonists abruptly. For mothers on clonidine through pregnancy who plan to breastfeed, consider switching to a more BF-compatible alternative 4–5 days before delivery to avoid the transplacental + milk co-exposure scenario in Sevrez 2014.10 |
| Viloxazine (discontinued during pregnancy per FDA recommendation) | If resuming postpartum: acceptable (RID ~1%). If patient has not tried atomoxetine or MPH, consider those first (more infant outcome data). Viloxazine reaches steady state in 2 days — a practical advantage over atomoxetine for postpartum resumption.7 |
| Any medication (discontinued during pregnancy) | Resume as early as possible postpartum (ideally 24–48 hours). The postpartum period is the highest-demand period for executive function. Stimulants provide fastest onset; atomoxetine requires 4–6 weeks — consider bridging with MPH during atomoxetine titration. |
The "Both/And" Framing
A mother who cannot safely drive, manage medications, or maintain infant care routines is not well-served by a breastfeeding-at-all-costs approach — nor by a medication-at-all-costs approach that unnecessarily forgoes breastfeeding.
The clinical conversation should never be framed as "breastfeeding OR medication." For most patients, the answer is "both, with monitoring." The benefits of breastfeeding (immunologic protection, nutritional optimization, bonding, reduced NEC risk in preterm infants) are well-established.15 The benefits of maternal ADHD treatment are also well-established. The course's job is to support both simultaneously.
VComorbid Postpartum Depression: The SSRI Interaction Map
ADHD-PPD comorbidity is common (some series report 30–50% overlap). The choice of SSRI matters for ADHD medication safety — particularly for atomoxetine, where strong CYP2D6 inhibitors increase exposure 6- to 8-fold.
| SSRI | CYP2D6 Effect | Atomoxetine Interaction | Breastfeeding Safety | Recommendation |
|---|---|---|---|---|
| Sertraline | Minimal inhibition | No significant effect on atomoxetine levels | Preferred for BF (low RID, extensive data; most common BF-exposed psychotropic in Liu 2025 Danish cohort — 56% of antidepressant exposures) | First-line for ADHD-PPD comorbidity during BF17 |
| Escitalopram | Minimal inhibition | No significant effect | Preferred for BF | First-line alternative |
| Citalopram | Minimal inhibition | No significant effect | Compatible (17.7% of antidepressant BF exposures in Liu 2025) | Acceptable alternative17 |
| Fluoxetine | Strong CYP2D6 inhibitor | Increases atomoxetine AUC 6–8 fold | Long half-life (norfluoxetine 4–6 days); infant irritability reported | Avoid with atomoxetine; avoid if possible during BF |
| Paroxetine | Strong CYP2D6 inhibitor | Increases atomoxetine AUC 6–8 fold | Low RID but first-trimester teratogenicity concern | Avoid with atomoxetine |
| Bupropion | Moderate CYP2D6 inhibitor | Increases atomoxetine exposure modestly | Compatible with BF; useful for ADHD-PPD-smoking cessation triad | Use with caution if on atomoxetine; monitor |
If a breastfeeding mother is on atomoxetine and needs an SSRI for PPD, use sertraline or escitalopram. If she is on a stimulant, any SSRI is acceptable from a drug interaction standpoint — but sertraline and escitalopram remain preferred for breastfeeding safety. The single most common postpartum prescribing trap is starting fluoxetine in a patient stable on atomoxetine without adjusting either; this functionally converts the patient into a "CYP2D6 PM" and raises atomoxetine RID 6–8 fold.
VIMonitoring Master Protocol
A unified monitoring protocol applicable across all ADHD medication classes during breastfeeding, with class-specific additions layered on top of the universal core.
Every Postpartum Visit (All Classes)
- Infant sleep, feeding, irritability, weight gain assessed
- Maternal ADHD function — driving safe? Infant care adequate? Appointments kept?
- Maternal mood — PPD/PPA screen (PHQ-9 or EPDS)
- Medication dose — still at lowest effective? Any escalation needed?
- Medication adherence and refill timing appropriate
- Co-medication review for new interactions (especially CYP2D6 for atomoxetine, CYP1A2 for viloxazine)
- Breastfeeding plan reassessed for ongoing appropriateness
Class-Specific Additions
Per FDA label: monitor infant for agitation, insomnia, anorexia, reduced weight gain. Milk supply monitoring is theoretical (no clinical reports of failure). At the lowest RID of any stimulant with the largest case-report base, monitoring intensity is the lightest of any ADHD agent during breastfeeding.2
CYP2D6 inhibitor check at every visit (especially postpartum SSRI switches); hepatic symptom screen for jaundice, RUQ pain, dark urine, pruritus (FDA warning); mood/suicidality assessment (FDA boxed warning). The PPD-CYP2D6 interaction trap is the most common postpartum prescribing error for atomoxetine.3,4
Milk supply monitoring (FDA warns of prolactin suppression at higher doses; mechanism is dopaminergic); infant irritability/sleep assessment (mild AEs in ~38% per Benassayag Kaduri 2024). Document FDA label override at every visit.5,6
CYP1A2 interaction check; caffeine intake counseling at every visit (strong CYP1A2 inhibitor; caffeine AUC increased 4.4–5.8 fold per Wang 2024; neonatal caffeine half-life ~97 hours in term newborns, up to 230 hours in preterm); mood/suicidality assessment (FDA boxed warning); HR/BP at 2, 6, 12 weeks. The caffeine counseling is unique to viloxazine and is the most actionable counseling point of any ADHD medication during breastfeeding.7,8,18
Infant sedation, hypotonia, tachypnea, poor feeding assessment; maternal BP monitoring (rebound HTN risk if doses missed); taper plan confirmed in chart; all providers aware medication cannot be stopped abruptly. Highest infant-serum concentration of any ADHD medication (~50% of maternal).9,11
Infant sedation, lethargy, poor feeding assessment; maternal BP monitoring; taper plan confirmed; CYP3A4 interaction check (fluconazole, clarithromycin, ritonavir increase guanfacine exposure 2–3 fold). Lower threshold for clinical concern given absence of human BF data.12
Reassessment Schedule (All Classes)
- 2 weeks postpartum: Initial check — infant tolerating? Milk supply established? Maternal function adequate?
- 6 weeks postpartum: Standard postpartum visit — reassess dose, supply, infant growth, maternal mood. For atomoxetine resumption: should be reaching therapeutic effect by this visit.
- 3 months postpartum: If all stable, continue with standard pediatric monitoring at well-child visits.
VIIUnresolved Questions & Future Directions
BF exposure increase
(Denmark 2012–2022)
BF psychostimulant
exposure (Liu 2025)
cohort to date
(Yamada, viloxazine)
18 months follow-up
1. Long-term neurodevelopmental outcomes of breast milk exposure
The Liu 2025 Danish population study documented a 6.80-fold increase in psychostimulant exposure among exclusively breastfed infants between 2012 and 2022 (from 0.4 to 2.7 per 1000 infants; methylphenidate accounted for 89% of these exposures). The authors note that the long-term neurodevelopmental effects of early infant exposure to psychostimulants via breast milk remain under-researched. No published study has followed breastfed infants exposed to any ADHD medication beyond 18 months (the longest follow-up is Benassayag Kaduri 2024 for amphetamines). This is the single largest evidence gap in the field.17,6
2. Guanfacine human milk data
Guanfacine has zero human milk data — only rat data showing milk concentrations comparable to blood.12 Given its increasing use for ADHD (particularly in patients with comorbid anxiety or tics), human milk PK data are urgently needed. An InfantRisk Center Human Milk Biorepository study analogous to Yamada 2025 (atomoxetine) would close this gap.
3. Viloxazine infant outcome data
The FDA label now contains measured milk PK data (RID ~1%), but zero infant outcome data exist. The Supernus lactation study (NCT06259331) was a PK-only design by protocol; mother-infant pairs were intentionally excluded. A follow-up study including breastfed infants would close this gap and should be prioritized.7
4. CYP2D6 PM-specific atomoxetine milk data
The Yamada 2025 study did not stratify by CYP2D6 genotype. Confirming that the theoretical PM RID (~1.9% mean, ~6.5% worst-case) matches empirical measurements would close an important safety gap for the ~7% of Caucasian patients (and lower proportions in other populations) with PM status.3,19
5. Dose-response relationships for milk supply effects
The prolactin-suppression data for amphetamines (DeLeo 1983) used IV and high-dose oral administration in the immediate postpartum period. Whether therapeutic oral doses at standard ADHD ranges meaningfully affect milk supply in established lactation remains unconfirmed.20
6. Real-world prevalence trends
The Liu 2025 Danish data are the only population-level descriptive data on ADHD medication BF exposure. Similar data from US, UK, and other large healthcare systems would help quantify the scale of the clinical need and identify regional prescribing patterns.17
VIIIThe 10 Commandments of ADHD Pharmacotherapy in Breastfeeding
Thou shalt not withhold breastfeeding for ADHD medication alone.
ACOG recommends against withholding mental-health medications due to lactation status alone. The AAP states most maternal medications are compatible with breastfeeding. The benefits of breastfeeding are well-established; the risks of ADHD medication exposure via milk are small and manageable.13,15
Thou shalt prefer methylphenidate or atomoxetine.
These are the Tier 1 agents: lowest RIDs (0.16–0.7% and 0.19%), most reassuring infant outcome data, and FDA labels that support breastfeeding via shared decision-making language. One is a stimulant, one is not — covering both clinical scenarios.1,3
Thou shalt not reflexively stop amphetamines.
The FDA label says "not recommended," but no serious adverse effects have been reported at therapeutic doses, and LactMed supports use with monitoring. If the patient is stable on amphetamines and a switch to methylphenidate would compromise ADHD control during the demanding postpartum period, continuation is a reasonable, evidence-supported option — with documented FDA label override.5,11
Thou shalt check CYP2D6 for atomoxetine.
A 10-fold exposure variation based on genotype is not a footnote — it directly affects milk concentrations. Test before conception when feasible. Review co-medications for CYP2D6 inhibitors at every visit. Use sertraline or escitalopram, not fluoxetine or paroxetine, for comorbid PPD.3,19
Thou shalt counsel caffeine restriction for viloxazine.
Viloxazine's strong CYP1A2 inhibition increases caffeine AUC 4.4–5.8 fold. Term newborns have caffeine half-lives of ~97 hours; preterm infants up to 230 hours. The combination of potentiated maternal caffeine + meaningful caffeine RID in milk + minimal neonatal clearance creates a compounding exposure unique to this agent. Counsel and document at every visit.7,8,18
Thou shalt never abruptly stop an alpha-2 agonist.
Rebound hypertension is dangerous postpartum. Document the taper plan. Tell every provider. This commandment carries over unchanged from the pregnancy course.
Thou shalt treat the mother.
The postpartum period is the highest-demand period for executive function. Untreated ADHD impairs driving safety, infant care, medication management, appointment adherence, and emotional regulation. A mother who cannot function safely is not well-served by withholding treatment to enable breastfeeding.13,14
Thou shalt monitor the infant.
Standard pediatric monitoring (sleep, feeding, irritability, weight gain) at 2 weeks, 6 weeks, and 3 months postpartum is sufficient for Tier 1 agents. Tier 2 and 3 agents warrant closer monitoring — particularly for amphetamines (mild AEs in ~38% per Benassayag Kaduri 2024) and clonidine (sedation, hypotonia, apnea risk).6,9
Thou shalt document the conversation.
For methylphenidate and atomoxetine, documentation aligns with the FDA label. For amphetamines, documentation must explicitly acknowledge the FDA "not recommended" language and the clinical rationale for overriding it. For viloxazine, documentation should acknowledge the January 2025 label update and the absence of infant outcome data. For all agents: document risk-benefit discussion, patient's informed choice, and monitoring plan.
Thou shalt use the lowest effective dose.
RID is dose-proportional for all ADHD medications. If the patient was dose-escalated during pregnancy (blood volume expansion, increased renal clearance, induced metabolism), the postpartum period is an opportunity to return to the pre-pregnancy dose — reducing both maternal side effects and infant exposure simultaneously.
IXIntegration with the Pregnancy Course
This breastfeeding companion course has covered the five pharmacologic classes used to treat ADHD during lactation: amphetamines, methylphenidate, alpha-2 adrenergic agonists, atomoxetine, and viloxazine. Each chapter integrated the available PK data, FDA label language, published infant outcomes, and expert consensus into a practical clinical workflow.
The Course in One Sentence
For breastfeeding mothers with ADHD, methylphenidate and atomoxetine are the Tier 1 agents with the lowest milk transfer and most reassuring safety data; amphetamines are acceptable with monitoring despite the FDA label; and the clinical priority is supporting both breastfeeding and maternal ADHD treatment simultaneously.
Integration Points with the Pregnancy Course
The pregnancy and breastfeeding courses are designed to be used together:
- Pre-conception: The pregnancy course drives medication selection (teratogenicity, obstetric risk). The breastfeeding course should inform the pre-conception discussion if breastfeeding is planned — particularly the amphetamine-to-methylphenidate switch decision and the CYP2D6 testing decision for atomoxetine.
- Third trimester: The breastfeeding plan should be finalized. If a class switch is needed for breastfeeding (e.g., amphetamine → methylphenidate, or pre-delivery clonidine switch per Sevrez lesson), late T3 is the optimal window.
- Delivery: Communicate medication use to anesthesia, OB, pediatrics, and lactation. Class-specific anesthesia considerations from the pregnancy course carry forward (especially amphetamine + halogenated agents, clonidine + neuraxial considerations).
- Postpartum: The breastfeeding course takes over. Resume or switch medications as early as possible. Monitor infant and milk supply per the protocols in this course.
The Pregnancy-Breastfeeding Hierarchy Comparison
| Feature | Pregnancy Preferred | Breastfeeding Preferred |
|---|---|---|
| Stimulant of choice | Methylphenidate (largest safety database) or amphetamine if stable on it | Methylphenidate (lowest RID, undetectable in infant serum) |
| Non-stimulant of choice | Depends on context: atomoxetine (largest T1 dataset, n=~990) or alpha-2 agonists for specific comorbidities (tics, anxiety, refractory HTN); none is reflexively first-line | Atomoxetine (RID 0.19%, Yamada 2025; lowest of any ADHD medication) |
| Agent to avoid | Viloxazine (FDA: "discontinue when pregnancy is recognized") | None absolute — but guanfacine has no human data; clonidine has high RID and one adverse event case |
| Key monitoring focus | BP, preeclampsia, fetal growth, NAS at delivery | Infant sleep, feeding, weight gain, milk supply |
| Key pharmacogenomic variable | CYP2D6 (atomoxetine) | CYP2D6 (atomoxetine) — same; effect carries forward |
| Key drug interaction | Antacids/PPIs (amphetamines, pH-dependent renal clearance) | CYP2D6 inhibitors (atomoxetine); strong CYP1A2 (viloxazine + caffeine) |
| FDA label tension | Viloxazine only ("discontinue") | Amphetamines only ("not recommended" vs. clinical practice) |
| Pregnancy-breastfeeding paradox | — | Viloxazine: avoid in pregnancy, acceptable in BF (different biology of exposure) |
XCourse Closing
How to Use This Course
Each chapter is designed to be used at three levels:
- The 60-Second Read (Bottom Line): for the prescriber making a rapid decision at the point of care.
- The Decision Algorithm and Clinic-Ready Tools: for structured workflow integration — the EMR templates, visit checklists, and patient scripts can be adapted into local clinical practice.
- The full evidence sections: for complex cases requiring deeper engagement with the primary PK data, drug interactions, or special populations.
The Evidence Base Is Evolving Rapidly
The evidence base for ADHD medications in breastfeeding has shifted substantially within the past year:
- Yamada 2025 (J Clin Psychopharmacol, epub November 2025): atomoxetine RID 0.19% from n=10 lactating participants — transformed atomoxetine from "no data, use caution" to Tier 1 for breastfeeding.3
- Qelbree FDA label update (January 27, 2025): added n=15 lactation PK study, RID ~1%; made viloxazine the first ADHD treatment to fulfill the FDA's 2019 Clinical Lactation Studies post-marketing requirement.7
- Liu 2025 Danish population data (Paediatr Perinat Epidemiol September 2025): documented the scale of psychostimulant exposure via breast milk in a national registry (6.80-fold increase 2012–2022; methylphenidate 89% of exposures).17
- Benassayag Kaduri 2024 (Psychiatry Res): largest prospective amphetamine-breastfed infant cohort to date (n=13); ~38% mild adverse reactions, no serious AEs.6
- Onyda XR and Javadin FDA approvals (2024–2025): updated clonidine products with modern lactation language.9
The principles in this course — methylphenidate and atomoxetine as Tier 1, amphetamines acceptable with monitoring, CYP2D6 vigilance for atomoxetine, strict caffeine restriction for viloxazine, never abruptly stop alpha-2 agonists — are likely to remain durable even as new data emerge.
The Final Word
REFReferences
- Concerta (methylphenidate hydrochloride) extended-release tablets drug label. Janssen Pharmaceuticals. Section 8.2 Lactation: "RID 0.16% to 0.7%... There are no reports of adverse effects on the breastfed infant or effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for CONCERTA." Accessed via DailyMed and accessdata.fda.gov.
- Methylphenidate and breast-feeding. Ann Pharmacother. 2006;40(10):1890–1891. doi: 10.1345/aph.1H159. PMID: 16940409.
- Atomoxetine as a viable ADHD treatment in breastfeeding mothers: evidence from human milk pharmacokinetic analysis. J Clin Psychopharmacol. 2026 Jan-Feb;46(1):16–22. doi: 10.1097/JCP.0000000000002109. Epub 2025 Nov 26. PMID: 41427840. (n=10 InfantRisk Center Human Milk Biorepository; RID 0.19%; no adverse effects.)
- Strattera (atomoxetine hydrochloride) capsules drug label. Eli Lilly and Company. Section 8.2 Lactation: "There are no data on the presence of atomoxetine or its metabolite in human milk... The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for STRATTERA." Accessed via DailyMed.
- Adderall XR (mixed amphetamine salts) extended-release capsules drug label. Takeda Pharmaceuticals; revised 2025. Section 8.2 Lactation: "Amphetamine is present in human milk, at relative infant doses of 2 to 13.8%... advise patients that breastfeeding is not recommended." Accessed via DailyMed.
- Amphetamine use for attention deficit hyperactive disorder during breastfeeding and children's neurodevelopmental outcomes: a pilot study. Psychiatry Res. 2024;339:116047. doi: 10.1016/j.psychres.2024.116047. PMID: 38908263. (n=13 mother-infant pairs; mild AEs ~38%; normal Denver/PedsQL outcomes through follow-up.)
- Qelbree (viloxazine extended-release capsules) drug label, NDA 211964/S-013. Supernus Pharmaceuticals; revised January 27, 2025. Section 8.1 Pregnancy: "Discontinue Qelbree when pregnancy is recognized." Section 8.2 Lactation: n=15 lactation study; RID ~1% viloxazine, 0.07% 5-HVLX-gluc; "These data support that transfer of viloxazine into breastmilk is low." Accessed via accessdata.fda.gov: label PDF 211964s013lbl.
- Impact of viloxazine extended-release capsules (Qelbree) on select cytochrome P450 enzyme activity and evaluation of CYP2D6 genetic polymorphisms on viloxazine pharmacokinetics. Clin Drug Investig. 2024;44(5):303–317. doi: 10.1007/s40261-024-01356-0. PMID: 38598106. (Caffeine AUC increased 4.4–5.8 fold; viloxazine is a strong CYP1A2 inhibitor.)
- Onyda XR (clonidine hydrochloride) extended-release oral suspension drug label. NextWave/Azurity Pharmaceuticals. Section 8.2 Lactation: "RID 4.1% to 8.4%... Exercise caution when ONYDA XR is administered to a nursing woman." Accessed via DailyMed.
- [Transplacental or breast milk intoxication to clonidine: a case of neonatal hypotonia and drowsiness]. Arch Pédiatr. 2014;21(2):198–200. doi: 10.1016/j.arcped.2013.11.004. PMID: 24411570.
- Clonidine. Drugs and Lactation Database (LactMed®). Bethesda, MD. NBK501628. "Because of the high serum levels found in some breastfed infants, possible infant side effects, and the possible negative effects on lactation, other antihypertensive agents are preferred, especially while nursing a newborn or preterm infant."
- Intuniv (guanfacine extended-release) drug label. Takeda Pharmaceuticals. Section 8.2 Lactation: "There are no data on the presence of guanfacine in human milk or the effects on the breastfed infant. The effects on milk production are also unknown. Guanfacine is present in the milk of lactating rats." Accessed via DailyMed.
- Treatment and management of mental health conditions during pregnancy and postpartum: ACOG Clinical Practice Guideline No. 5. Obstet Gynecol. 2023;141(6):1262–1288. doi: 10.1097/AOG.0000000000005202.
- Medication safety in breastfeeding. Am Fam Physician. 2022;106(6):638–644.
- Technical report: breastfeeding and the use of human milk. Pediatrics. 2022;150(1):e2022057989.
- Methylphenidate. Drugs and Lactation Database (LactMed®). Bethesda, MD. NBK501310. "If methylphenidate is required by the mother, it is not a reason to discontinue breastfeeding."
- Psychotropic medication exposure via breast milk: a population-based descriptive study in Denmark. Paediatr Perinat Epidemiol. 2025;39(7):612–625. doi: 10.1111/ppe.70074. (Psychostimulant BF exposure increased 6.80-fold from 0.4 to 2.7 per 1000 infants 2012–2022; methylphenidate 89% of psychostimulant exposures; sertraline 56% of antidepressant exposures.)
- Pharmacokinetics, pharmacodynamics and metabolism of caffeine in newborns. Semin Fetal Neonatal Med. 2020;25(6):101183. (Term newborn caffeine plasma half-life ~97 hours; preterm range 40–230 hours; reaches adult levels at 3–4.5 months.)
- Clinical Pharmacogenetics Implementation Consortium guideline for cytochrome P450 (CYP)2D6 genotype and atomoxetine therapy. Clin Pharmacol Ther. 2019;106(1):94–102. doi: 10.1002/cpt.1409. PMID: 30801677.
- Prolactin lowering effect of amphetamine in normoprolactinemic subjects and in physiological and pathological hyperprolactinemia. Horm Metab Res. 1983;15(9):439–443.
- Transfer of dexamphetamine into breast milk during treatment for attention deficit hyperactivity disorder. Br J Clin Pharmacol. 2007;63(3):371–375. PMID: 17302898.
- Pharmacokinetics of clonidine during pregnancy and nursing. Obstet Gynecol. 1987;69(4):598–600. PMID: 3822302.
- Clinical pharmacokinetics of atomoxetine. Clin Pharmacokinet. 2005;44(6):571–590. PMID: 15910008.
- Pharmacological treatment of attention deficit hyperactivity disorder during pregnancy and lactation. Pharm Res. 2018;35(3):46. doi: 10.1007/s11095-017-2323-z. PMID: 29411149.
- The effects of drugs used for the treatment of ADHD on pregnancy outcome and breast-feeding: a critical review. Curr Neuropharmacol. 2021;19(11):1794–1804.
- Attention-deficit/hyperactivity disorder in pregnancy and the postpartum period. Am J Obstet Gynecol. 2024;231(1):19–35. PMID: 38432409.
- Quantification of ADHD medication in biological fluids of pregnant and breastfeeding women with liquid chromatography: a comprehensive review. Front Public Health. 2024;12:1437328.
- Evaluation of the Excretion of Viloxazine and Its Metabolite 5-Hydroxy-viloxazine Glucuronide Into Breast Milk Following Multiple Doses of SPN-812 (600 mg, QD) in Healthy Lactating Women (Protocol 812P418). ClinicalTrials.gov NCT06259331. Completed September 20, 2023.
- Clinical Lactation Studies: Considerations for Study Design — Guidance for Industry. Center for Drug Evaluation and Research; May 2019.
- Managing attention-deficit/hyperactivity disorder in a breastfeeding mother: a case report. Pharmacotherapy. 2025;45(8):529–534. PMID: 40536085.
Responses